Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05692570 · ClinicalTrials.gov registry record · Phase 1
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
A Phase 1 study, sponsored by Pyramid Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05692570 is a Phase 1 study that has completed, run by Pyramid Biosciences. The registered enrollment target is 21 participants.
The verdict
NCT05692570, a Phase 1 study, has completed, sponsored by Pyramid Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a drug-drug interaction study in volunteers to evaluate the effect of ritonavir or cobicistat on the pharmacokinetics (PK) of PBI-200.
Interventions
- DRUG PBI-200 Tablet
- DRUG Ritonavir Oral Tablet
- DRUG Cobicistat Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-09-09 |
| Est. Completion | 2022-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05692570
The ClinicalTrials.gov registry entry for NCT05692570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pyramid Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PBI-200 Tablet is the first listed.
NCT05692570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05692570 about?
NCT05692570 is a clinical study titled "A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers". This is a drug-drug interaction study in volunteers to evaluate the effect of ritonavir or cobicistat on the pharmacokinetics (PK) of PBI-200.
What is the current status of trial NCT05692570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-09-09. Estimated completion is 2022-11-12.
What interventions are being tested in trial NCT05692570?
The interventions under investigation include: PBI-200 Tablet (DRUG), Ritonavir Oral Tablet (DRUG), Cobicistat Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05692570?
This trial is sponsored by Pyramid Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.